Čerňan Martin, Szotkowski Tomáš, Minařík Jiří, Kolář Milan, Sauer Pavel, Látal Vojtěch, Zapletalová Jana, Papajík Tomáš
Department of Haemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, I.P. Pavlova 6, 77 900 Olomouc, Czech Republic.
Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Hněvotínská 3, 77 515 Olomouc, Czech Republic.
Life (Basel). 2022 Aug 3;12(8):1184. doi: 10.3390/life12081184.
Vaccination is an important tool in the fight against the COVID-19 pandemic in patients with haematologic malignancies. The paper provides an analysis of the course of breakthrough SARS-CoV-2 infection in a group of vaccinated patients with haematological malignancy and a comparison with a historical cohort of 96 non-vaccinated patients with haematologic malignancies and bone marrow failure syndromes (two patients) in the treatment of COVID-19. A severe or critical course of COVID-19 was significantly less frequent in the group of vaccinated patients (10.2% vs. 31.4%, p = 0.003). The need for hospitalisation due to COVID-19 was significantly lower in vaccinated patients (27.1% vs. 72.6%, p < 0.0001) and the duration of hospitalisation was significantly shorter (10 vs. 14 days, p = 0.045). Vaccinated patients were insignificantly less likely to require oxygen therapy during infection. COVID-19 mortality was significantly higher in non-vaccinated patients (15.6% vs. 5.1%, p = 0.047). The paper demonstrated a significant positive effect of vaccination against COVID-19 on a less severe clinical course of infection, lower need for hospitalisation and mortality. However, the results need to be evaluated even in the context of new antivirals and monoclonal antibodies against SARS-CoV-2 or virus mutations with different biological behaviour.
接种疫苗是血液系统恶性肿瘤患者抗击新冠疫情的一项重要工具。本文分析了一组接种疫苗的血液系统恶性肿瘤患者中突破性SARS-CoV-2感染的病程，并与96例未接种疫苗的血液系统恶性肿瘤和骨髓衰竭综合征患者（两名患者）治疗新冠的历史队列进行了比较。接种疫苗的患者中新冠病情严重或危急的情况明显较少（10.2%对31.4%，p = 0.003）。接种疫苗的患者因新冠住院的需求显著更低（27.1%对72.6%，p < 0.0001），且住院时间明显更短（10天对14天，p = 0.045）。接种疫苗的患者在感染期间需要吸氧治疗的可能性略低。未接种疫苗的患者新冠死亡率显著更高（15.6%对5.1%，p = 0.047）。本文证明了接种新冠疫苗对减轻感染的临床病程、降低住院需求和死亡率具有显著的积极作用。然而，即使在有针对SARS-CoV-2的新型抗病毒药物和单克隆抗体或具有不同生物学行为的病毒突变的背景下，这些结果仍需评估。
